SecBot SecBot

TEVA drug pipeline

$44.50
+1.9% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.5%
1-day, median of 26 events
IV rank
No data
No current options data
Rated drugs
9
1 bearish · 8 neutral
Phase 3 trials
14
2 with results posted

Upcoming catalysts

1 dated
  1. Dec 2026
    TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
    Phase 3 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved (in-hospital); sNDA under FDA review for at-home use
Time to marketAlready approved as IGALMI for in-hospital use. The at-home label expansion decision is due by November 14, 2026 PDUFA date. If approved, commercial launch for at-home use would follow shortly after, led by Teva.

BXCL-501 dexmedetomidine Updated Nov 3

What to watch

The PDUFA decision on November 14, 2026 is the key catalyst. An approval would validate Teva's $57.5M acquisition and open a first-to-market at-home agitation market. A CRL would be a setback but not devastating for Teva given its diversified portfolio. Watch for any FDA AdComm announcement or pre-PDUFA news flow in the coming days.

Bull case
  • If approved by the November 14 PDUFA, BXCL-501 would be the first and only FDA-approved at-home treatment for acute agitation, addressing a large unmet need with an estimated 86 million annual episodes and up to 1.8 million eligible US patients.
  • Teva acquired the asset at a distressed price ($57.5M upfront) from BioXcel's Chapter 11 bankruptcy, giving it a potentially blockbuster indication with minimal upfront cost and a built-in commercial infrastructure.
  • Teva's Q3 2026 earnings beat estimates (EPS $0.86 vs $0.72 consensus) and the company is executing its Pivot to Growth strategy, with strong neuroscience brand growth (AUSTEDO +21%, AJOVY +61%, UZEDY +96% YoY) providing a commercial platform for BXCL-501.
Bear case
  • The FDA could issue a Complete Response Letter (CRL) on November 14, delaying or rejecting the at-home label expansion, which would significantly reduce the value of Teva's acquisition and trigger lower contingent payments.
  • IGALMI's in-hospital sales have been falling (contributing to BioXcel's bankruptcy), raising questions about commercial adoption even if at-home use is approved.
  • Teva faces ongoing generic erosion headwinds (total Q3 revenue declined 2% YoY) and the BXCL-501 deal is small relative to Teva's overall $16B+ revenue base, limiting its stock-moving potential.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market — first approved April 2017; Austedo XR approved February 2023

AUSTEDO deutetrabenazine Updated Aug 24

What to watch

Austedo is a mature, approved revenue driver for Teva, commercial execution and growth trajectory matter more than any single catalyst. Watch Teva's quarterly innovative brand revenue growth rate (43% LC YoY in H1 2026) and any label-expansion trial updates for downward drift potential, as the binary approval catalysts are years past.

Bull case
  • Austedo is Teva's largest innovative brand with an ~$1.4B annualized revenue run-rate based on H1 2026 figures of ~$696M, driving robust 43% LC YoY growth for the innovative brand portfolio.
  • Teva raised its 2026 combined revenue outlook for Austedo, Ajovy, and Uzedy to ~$3.7B, reflecting strong commercial momentum and market share gains.
  • Austedo XR (once-daily formulation) expands the addressable patient population with a convenience advantage over twice-daily immediate-release formulations.
Bear case
  • Austedo faces competitive pressure from Neurocrine's Ingrezza (valbenazine), the first-mover in tardive dyskinesia with a larger commercial presence and established brand recognition.
  • As a large-cap pharma drug within a $36.9B market-cap company, even significant Austedo revenue beats have limited single-stock impact, the drug is ~8-10% of Teva's total revenue.
  • Generics erosion of Teva's legacy products (U.S. generics -31% YoY in Q2 2026) and a heavy debt load ($16.6B, 68% leverage) are macro overhangs.
● neutral
Impact
PhaseApproved
Time to marketAlready FDA-approved (September 25, 2026). Teva plans to launch DEGEVMA commercially in the coming months.

DEGEVMA denosumab-adet Updated Nov 3

What to watch

DEGEVMA is already FDA-approved (Sep 25, 2026) with no upcoming binary regulatory catalyst. Watch for Teva's commercial launch timing and market-share capture in a crowded denosumab biosimilar field (10+ rivals). Teva's Q3 2026 earnings (reported Nov 3, 2026) may provide launch and revenue commentary.

Bull case
  • DEGEVMA is FDA-approved as interchangeable with Xgeva, which may allow pharmacy-level substitution without prescriber involvement.
  • Together with Ponlimsi (Prolia biosimilar, approved Mar 2026), Teva has a complete denosumab portfolio covering both oncology (Xgeva) and osteoporosis (Prolia) indications.
  • Teva developed DEGEVMA internally, which may support better margins versus licensed-in biosimilars.
Bear case
  • Extremely crowded market: at least 10 denosumab biosimilars are approved in the US, making it difficult for any single entrant to capture significant share.
  • Xgeva (reference product) sales are already declining (down 20% YoY in Q4 2025 per Amgen), shrinking the addressable market that biosimilars compete over.
  • Teva is a large, diversified company ($4.4B quarterly revenue) so DEGEVMA alone is unlikely to be a needle-moving catalyst for the stock.
● neutral
Impact
PhaseApproved
Time to marketEticovo is already FDA-approved (since 2019) but is blocked from U.S. commercial launch by Amgen's patent injunction until at least 2029. Teva obtains U.S. commercialization rights upon deal close (expected by end of 2026), but cannot generate revenue until the patent barrier lifts.

ETICOVO etanercept-ykro Updated Nov 3

What to watch

The key event is today's (Nov 3, 2026) deal with Samsung Bioepis giving Teva U.S. commercialization rights to Eticovo upon close. However, Eticovo remains blocked from the U.S. market by Amgen's Enbrel patents until at least 2029, so near-term revenue is zero. Watch for the deal closing (expected by end of 2026) and any patent-litigation developments that could shift the 2029 launch timeline.

Bull case
  • Teva secured U.S. commercialization rights to an already FDA-approved biosimilar (approved 2019) with a established safety and efficacy profile, avoiding development risk.
  • The deal expands Teva's biosimilar portfolio under its Pivot to Growth strategy, adding a product that targets a large autoimmune market (Enbrel had multi-billion-dollar annual sales before biosimilar erosion).
  • Analyst consensus on TEVA is strong buy (6 buy/strong-buy vs 1 hold, 0 sell) with a mean price target of $47.92, implying ~17.7% upside from the $40.70 close, per the latest snapshot.
Bear case
  • Eticovo is blocked from the U.S. market by a permanent injunction from Amgen's Enbrel patent litigation, preventing any sales until at least 2029, per multiple sources including Fierce Pharma and Drug Patent Watch.
  • Teva is a large, diversified pharma company (market cap implied ~$40B+ at ~$40/share), so Eticovo's potential contribution is small relative to the whole enterprise.
  • The deal's $420 million total value is split across two products (Eticovo and Renflexis) and is mostly milestone- and royalty-based, not guaranteed upfront cash.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market (FDA-approved since April 2017). Teva will take over US commercialization in Q3 2027.

infliximab-abda Updated Nov 3

What to watch

Watch for the closing of the Teva-Samsung Bioepis deal (expected by year-end 2026) and the Q3 2027 commercialization transfer of infliximab-abda. The key question is whether Teva can grow Renflexis market share in a crowded infliximab biosimilar field against Celltrion's Inflectra, Amgen's Avsola, and Pfizer's Ixifi.

Bull case
  • infliximab-abda (Renflexis) has been FDA-approved since 2017 with a proven track record of clinical efficacy and supply reliability, removing regulatory risk.
  • Teva gains US commercialization rights as part of a broader strategic partnership with Samsung Bioepis covering up to six biosimilar candidates, signaling long-term pipeline depth.
  • The biosimilar market for TNF inhibitors continues to grow as biologics lose patent protection and payers push for lower-cost alternatives.
Bear case
  • The infliximab biosimilar market in the US already has four approved competitors (Inflectra/Celltrion, Renflexis/Samsung Bioepis, Ixifi/Pfizer, Avsola/Amgen), making it a crowded, price-competitive space.
  • Teva does not take over commercialization until Q3 2027, nearly a year away, giving incumbents time to solidify market positions.
  • Teva is a large diversified company (~$17B annual revenue), so this single biosimilar will have a modest impact on overall financials even if successful.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available since November 2018 (oncology) and December 2019 (rheumatoid arthritis).

TRUXIMA rituximab-abbs Updated Nov 4

What to watch

TRUXIMA's next catalyst is the expiration of its first-interchangeable exclusivity period, which runs approximately 1 year from the July 1, 2026 FDA designation. Watch for whether a second interchangeable rituximab biosimilar (e.g. from Fresenius Kabi/Dr. Reddy's, approved August 2026) can enter the interchangeable market after that window closes. Also monitor Teva's Q4 2026 and full-year 2026 earnings for biosimilars revenue tracking against the $800M+ target.

Bull case
  • TRUXIMA became the first interchangeable rituximab biosimilar in the U.S. in July 2026, enabling pharmacy-level substitution without prescriber involvement, a significant commercial advantage.
  • The interchangeability designation grants TRUXIMA a roughly 1-year exclusivity period during which the FDA cannot approve another interchangeable rituximab biosimilar, protecting market position.
  • Teva's biosimilars portfolio (which includes TRUXIMA) is on track to exceed $800 million in 2026 revenue, achieving its original 2027 target one year early.
Bear case
  • New competition entered in August 2026: Fresenius Kabi and Dr. Reddy's received FDA approval for a separate rituximab biosimilar, which will pressure pricing and market share.
  • Teva's overall generics revenue declined 2% YoY in Q3 2026, and TRUXIMA sits within the generics/biosimilars segment that faces ongoing pricing erosion.
  • TRUXIMA is commercialized through a partnership with Celltrion (exclusive U.S./Canada rights since 2016), meaning Teva shares economics with its partner rather than keeping full margins.
● neutral
Impact
PhaseApproved
Time to marketAlready FDA-approved (October 8, 2026) and launching commercially in the US. Teva's inpatient free trial site indicates the product is preparing for commercial availability in the coming weeks. EMA review in Europe is ongoing with no decision date set.

WELTRUZA olanzapine Updated Nov 3

What to watch

WELTRUZA is already FDA-approved and launching; the next potential catalyst is an EMA decision on the MAA accepted in May 2026, though no specific date is set. Watch for early commercial uptake metrics in Teva's quarterly earnings and any formulary access wins, as these will signal whether the $1.5B-$2B franchise peak-sales target is credible.

Bull case
  • WELTRUZA is the first and only once-monthly subcutaneous olanzapine LAI that requires no loading dose, no oral supplementation, and no mandatory post-injection observation, a major convenience advantage over the only other long-acting olanzapine (Zyprexa Relprevv, which requires a 3-hour monitored observation).
  • Teva management targets $1.5B-$2B in combined peak annual sales for the Uzedy/Weltruza schizophrenia franchise, and Uzedy alone grew 43% YoY to $77M in Q2 2026, showing momentum.
  • The Phase 3 SOLARIS trial supported approval with a safety/efficacy profile consistent with oral olanzapine, and the drug addresses a large addressable market of roughly 300,000 US patients on oral olanzapine.
Bear case
  • Olanzapine is a 30-year-old generic drug; payers may resist a premium-priced branded LAI when cheap oral generics exist, pressuring uptake and pricing.
  • Teva's Uzedy (risperidone LAI) generated only $77M in Q2 2026, suggesting the schizophrenia LAI market has been slow to adopt new entrants; Weltruza faces the same commercial challenge.
  • Weight gain and metabolic side effects are well-known with olanzapine and could limit prescribing despite the convenience advantage.
● neutral
Impact
PhaseApproved
Time to marketAlready FDA-approved and commercially available since September 2018.

AJOVY fremanezumab Updated Aug 24

What to watch

With AJOVY already approved and generating steady revenue as part of Teva's innovative portfolio, watch the quarterly earnings calls for AJOVY sales trends relative to CGRP-class competitors (Emgality, Aimovig, Vyepti). The key TEVA catalyst to watch is the upcoming NDA submission for ecopipam (Tourette syndrome) in H2 2026, that's a more binary pipeline event than anything on AJOVY.

Bull case
  • AJOVY is a proven, FDA-approved CGRP inhibitor for migraine prevention with a convenient quarterly or monthly subcutaneous dosing option, a differentiating factor vs some competitors.
  • Teva's innovative products (including AJOVY plus AUSTEDO and UZEDY) grew 41% YoY in Q1 2026, showing strong commercial traction as Teva pivots away from pure generics.
  • Analyst consensus on TEVA is Strong Buy (6 Buy/Strong Buy out of 7 ratings) with a mean price target of $41.40, roughly 12% upside from the current ~$36.93 price.
Bear case
  • CGRP inhibitor market is intensely competitive with at least 3 other injectable anti-CGRP antibodies (Aimovig/erenumab from Amgen/Novartis, Emgality/galcanezumab from Lilly, Vyepti/eptinezumab from Lundbeck) plus oral CGRP antagonists (Nurtec, Ubrelvy, Qulipta) eroding share.
  • As an already-approved and mature drug, AJOVY faces ongoing payer/formulary pressure and biosimilar risk as the CGRP class ages, limiting revenue growth potential.
  • AJOVY is only one part of Teva's revenue, Q1 2026 showed innovative products grew 41% YoY but Teva's overall 2026 EPS guidance was lowered to $1.91-$2.11 from $2.57-$2.77 due to the Emalex acquisition, indicating margin pressure.
▼ bearish
Impact
PhasePhase 2
Time to marketNot estimable. The Phase 2 MSA study was discontinued for futility; the broader program's future is uncertain.

emrusolmin Updated Nov 2

What to watch

The Phase 2 TOPAS-MSA study was discontinued today (Nov 2, 2026) after an interim futility analysis, removing emrusolmin as a near-term pipeline catalyst. Teva says this is not a final decision on the broader program and will analyze open-label extension data, but no further development path or timeline has been outlined. For a diversified pharma like Teva, this is a modest pipeline setback; watch for any update on whether the Parkinson's disease program continues.

Bull case
  • No safety concerns were identified in the interim analysis, leaving the safety profile intact for potential future development.
  • Teva stated the discontinuation 'does not represent a final decision on the broader emrusolmin program' and will analyze open-label extension data.
  • Emrusolmin also has a Phase 1/2 trial in Parkinson's disease (a much larger market than MSA), which could still advance.
Bear case
  • Phase 2 TOPAS-MSA study discontinued after interim futility analysis met the criterion for low probability of meeting the primary endpoint, a clear efficacy failure signal.
  • Teva had previously guided to peak sales potential of more than $2 billion for emrusolmin in MSA; that revenue opportunity is now eliminated.
  • The broader emrusolmin program (including Parkinson's disease) is now in question given the mechanism-of-action failure in a related synucleinopathy.

Other drugs in filings and trials

no drug report yet
  • PONLIMSI Last: Approval · Mar 31, 2026
  • olanzapine LAI Last: NDA filed · Feb 28, 2026
  • ALVAIZ Last: Approval · Nov 29, 2023
  • PACLITAXEL Last: Approval · May 11, 2023
  • UZEDY Last: Approval · Apr 28, 2023
  • MICAFUNGIN Last: Approval · Jul 30, 2021
  • ROMIDEPSIN Last: Approval · Mar 13, 2020
  • FOSAPREPITANT DIMEGLUMINE Last: Approval · Sep 5, 2019
  • CASSIPA Last: Approval · Sep 7, 2018
  • ARMONAIR RESPICLICK Last: Approval · Jan 27, 2017
  • VANTRELA ER Last: Approval · Jan 17, 2017
  • CINQAIR Last: Approval · Mar 23, 2016
  • PROAIR RESPICLICK Last: Approval · Mar 31, 2015
  • ARGATROBAN IN 0.9% SODIUM CHLORIDE Last: Approval · Dec 15, 2014
  • DESVENLAFAXINE Last: Approval · Oct 11, 2013
  • QUARTETTE Last: Approval · Mar 28, 2013
  • ZECUITY Last: Approval · Jan 17, 2013
  • SYNRIBO Last: Approval · Oct 26, 2012
  • QNASL Last: Approval · Mar 23, 2012
  • Atenolol 50 MG 1 trial
  • Carboplatin-Paclitaxel adjuvant chemotherapy 1 trial
  • Celecoxib 1 trial
  • Gabapentin 1 trial
  • Levetiracetam 1 trial
  • Metformin 3 trials
  • paclitaxel/carboplatin 1 trial
  • Pentoxifylline 3 trials
  • Prazosin 1 trial
  • Sildenafil 1 trial
  • Tadalafil 20 MG 2 trials
  • TEV-48574 1 trial
  • TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen 1 trial
  • ursodiol (ursodeoxycholic acid, UDCA) 1 trial

Past FDA events & how the stock moved

26 events
DateDrugEvent1 day5 days
Oct 9, 2026WELTRUZAApproval+4.9%+5.7%
Sep 28, 2026DEGEVMAApproval+1.6%+1.2%
Mar 31, 2026PONLIMSIApproval+6.7%+7.7%
Mar 27, 2026PONLIMSIApproval−4.8%+0.1%
Feb 28, 2026olanzapine LAINDA filed−0.3%−8.3%
Nov 29, 2023ALVAIZApproval+0.2%+0.3%
May 11, 2023PACLITAXELApproval−3.8%−1.1%
Apr 28, 2023UZEDYApproval+3.8%+2.9%
Feb 17, 2023AUSTEDOApproval−1.8%−2.0%
Jul 30, 2021MICAFUNGINApproval+1.6%+3.3%
Mar 13, 2020ROMIDEPSINApproval−8.3%−6.8%
Sep 5, 2019FOSAPREPITANT DIMEGLUMINEApproval−1.3%+15.2%
Sep 14, 2018AJOVYApproval+5.5%+9.7%
Sep 7, 2018CASSIPAApproval−3.2%+5.1%
Aug 30, 2017AUSTEDOApproval+0.6%−1.9%
Apr 3, 2017AUSTEDOApproval−0.3%+1.3%
Jan 27, 2017ARMONAIR RESPICLICKApproval+1.7%+1.5%
Jan 17, 2017VANTRELA ERApproval+0.4%−4.0%
Mar 23, 2016CINQAIRApproval−0.9%−2.3%
Mar 31, 2015PROAIR RESPICLICKApproval+0.0%+6.4%
Dec 15, 2014ARGATROBAN IN 0.9% SODIUM CHLORIDEApproval−1.4%+4.2%
Oct 11, 2013DESVENLAFAXINEApproval−0.6%−1.4%
Mar 28, 2013QUARTETTEApproval+0.2%−0.7%
Jan 17, 2013ZECUITYApproval−0.2%−0.1%
Oct 26, 2012SYNRIBOApproval−0.9%−0.8%
Mar 23, 2012QNASLApproval+1.7%+4.4%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
TQB3616 capsules, Letrozole, Anastrozole, TamoxifenClinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast CancerPhase 3Active not recruiting1,946Dec 2026
CelecoxibNeuroinflammation in Patients With OCDPhase 2Completed18Oct 28, 2026
Fp/ABSA Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaPhase 3Completed649Oct 26, 2026
Olanzapine 10 milligramComparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency DepartmentPhase 3Completed31Sep 25, 2026
MesalamineDapagliflozin in Patients With Ulcerative ColitisPhase 3Completed60Aug 20, 2026
GabapentinGabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use DisordersPhase 2Completed51Jul 31, 2026
Ibuprofen 600 mgPreeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority TrialPhase 2Completed287Jun 15, 2026
OxaliplatinNo Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal CancerPhase 2Completed39May 5, 2026
DasatinibFortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot StudyPhase 2Completed23Apr 30, 2026
MetforminAdjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian SyndromePhase 3Completed200Mar 30, 2026
PentoxifyllineEvaluation of Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Obstructive JaundicePhase 2Completed45Mar 19, 2026
Pentoxifylline 400mg plus chemotherapyClinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer PatientsPhase 2Completed46Mar 15, 2026
ursodiol (ursodeoxycholic acid, UDCA)The Role of Secondary Bile Acids in Intestinal InflammationPhase 3Terminated2Mar 2, 2026
Letrozole 2.5mgComparative Evaluation of the Efficacy of Letrozole, L-Carnitine, and Their Combination on Sperm Quality, Oxidative Stress, and ART Outcomes in Men With Idiopathic Oligoasthenoteratozoospermia.Phase 3Completed90Feb 28, 2026
MetforminMetformin for Pulmonary Hypertension HFpEFPhase 2Completed33Feb 27, 2026
LevetiracetamTreating Hyperexcitability in AD With LevetiracetamPhase 2Completed58Feb 16, 2026
Atenolol 50 MGAtenolol for the Prevention of Osteoporosis (APO)Phase 2Completed420Feb 2, 2026
PrazosinPrazosin for Alcohol Use Disorder With Withdrawal SymptomsPhase 2Completed152Jan 30, 2026
Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, LeucovorinOxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic CancerPhase 2Completed40Dec 31, 2025
Anastrozole 1mgNeoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast CancerPhase 2Completed8Dec 9, 2025
BicalutamideAntiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by SurgeryPhase 3Completed612Oct 31, 2025
paclitaxel/carboplatinTrial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer PatientsPhase 2Completed · results79Oct 22, 2025
MetforminImprove PAD PERformance With METforminPhase 3Completed · results202Aug 20, 2025
AJOVYA Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and AdolescentsPhase 3Completed · results499Aug 15, 2025
Lansoprazole 15 mgStudy to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDsPhase 3Completed392Jul 1, 2025
Tadalafil 20 MGEffect of PDE5 Inhibition on Adipose Metabolism in HumansPhase 2Completed · results99Jun 20, 2025
ELP (Extended Letrozole Protocol)Extended Letrozole Protocol Versus Letrozole Plus Inositol for Induction of Ovulation in Letrozole Resistant PCOS WomenPhase 2Completed200Jun 1, 2025
Pentoxifylline 400 MGPhosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.Phase 2Completed60May 20, 2025
SildenafilSafety of Sildenafil in Premature InfantsPhase 2Completed · results109Mar 1, 2025
MetforminA Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLLPhase 2Completed · results37Feb 28, 2025
FluorouracilA Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ CancerPhase 2Terminated · results3Feb 20, 2025
Carboplatin-Paclitaxel adjuvant chemotherapyCarboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical CancerPhase 2Terminated21Jan 31, 2025
PaclitaxelIntravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal CarcinomatosisPhase 2Completed · results21Jan 27, 2025
Arsenic trioxideStudy for Patients With Newly Diagnosed, High-risk Acute Promyelocytic LeukemiaPhase 3Completed133Jan 20, 2025
CarboplatinComparing Photon Therapy To Proton Therapy To Treat Patients With Lung CancerPhase 3Completed330Jan 2, 2025
Metformin treatmentMethotrexate and Metformin in Rheumatoid Arthritis PatientsPhase 2Completed128Dec 19, 2024
CarboplatinNivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung CancerPhase 2Completed · results101Nov 13, 2024
TEV-48574A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseasePhase 2Completed · results290Nov 12, 2024
TamoxifenOral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer RiskPhase 2Terminated · results65Oct 15, 2024
Tadalafil 5mgComparsion of Effect of PRP,PDE5 Inhibitor in Treatment of Erectile DysfunctionPhase 3Completed75Aug 25, 2024